title: Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells.
abstract: Recent studies have shown that high insulin-like growth factor I (IGF-I) blood level is a risk factor in breast and prostate cancer. The aim of this study was to determine whether the mitogenic activity of IGF-I in mammary cancer cells can be reduced by the dietary carotenoid lycopene. The anticancer activity of lycopene, the major tomato carotenoid, has been suggested by in vitro, in vivo, and epidemiological studies. Growth stimulation of MCF7 mammary cancer cells by IGF-I was markedly reduced by physiological concentrations of lycopene. The inhibitory effects of lycopene on MCF7 cell growth were not accompanied by apoptotic or necrotic cell death, as determined by annexin V binding to plasma membrane and propidium iodide staining of nuclei in unfixed cells. Lycopene treatment markedly reduced the IGF-I stimulation of tyrosine phosphorylation of insulin receptor substrate 1 and binding capacity of the AP-1 transcription complex. These effects were not associated with changes in the number or affinity of IGF-I receptors, but with an increase in membrane-associated IGF-binding proteins, which were previously shown in different cancer cells to negatively regulate IGF-I receptor activation. The inhibitory effect of lycopene on IGF signaling was associated with suppression of IGF-stimulated cell cycle progression of serum-starved, synchronized cells. Moreover, in cells synchronized by mimosine treatment, lycopene delayed cell cycle progression after release from the mimosine block. Collectively, the above data suggest that the inhibitory effects of lycopene on MCF7 cell growth are not due to the toxicity of the carotenoid but, rather, to interference in IGF-I receptor signaling and cell cycle progression.
authors.affiliation: Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. yoav@bgumail.bgu.ac.il
authors.forename: M
authors.initials: M
authors.lastname: Karas
authors.forename: H
authors.initials: H
authors.lastname: Amir
authors.forename: D
authors.initials: D
authors.lastname: Fishman
authors.forename: M
authors.initials: M
authors.lastname: Danilenko
authors.forename: S
authors.initials: S
authors.lastname: Segal
authors.forename: A
authors.initials: A
authors.lastname: Nahum
authors.forename: A
authors.initials: A
authors.lastname: Koifmann
authors.forename: Y
authors.initials: Y
authors.lastname: Giat
authors.forename: J
authors.initials: J
authors.lastname: Levy
authors.forename: Y
authors.initials: Y
authors.lastname: Sharoni
mesh_terms: D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002338:Carotenoids / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects*; D016923:Cell Death / Q000187:drug effects; D002455:Cell Division; D004396:Coloring Agents; D004247:DNA / Q000032:analysis / Q000096:biosynthesis; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000494:pharmacology; D000077276:Lycopene; D011419:Propidium; D015398:Signal Transduction / Q000187:drug effects*; D014407:Tumor Cells, Cultured
chemical_list: D016588:Anticarcinogenic Agents; D004396:Coloring Agents; D002338:Carotenoids; D011419:Propidium; D007334:Insulin-Like Growth Factor I; D004247:DNA; D000077276:Lycopene